The funding was subscribed by a consortium of PharmaFluidics’ existing shareholders, new investors and management. Shareholders include Qbic Arkiv Fund, the Flemish investment company PMV, Theodorus Fund, Innovation Fund and Volksvermogen.
The funds will be used to expand the company’s team and efforts to commercialize its proprietary µPAC™ micro-chip based chromatography cartridges for use in biomarker, diagnostics and drug R&D applications worldwide.
Johan Devenyns, Managing Director PharmaFluidics: “Today, our µPAC™ cartridges already convincingly outperform state-of-the-art nano-LC columns currently used, as demonstrated by a variety of real-life proteomics, metabolomics and lipidomics lab analysis tests. Our micro-chip based chromatography cartridges provide substantial added value and time savings potential for biomarker and bio-similar developers. The renewed commitment of shareholders confirms their trust in the technology and potential of the company and team, associates and advisors”.
The key expertise and IP portfolio include the design, lithographic production, and surface treatment of silicon wafers for use as separation devices in liquid chromatography. PharmaFluidics collaborates with an extensive network of Centers of Excellence and pioneer users to develop an increasing range of applications.
About PharmaFluidics
PharmaFluidics develops molecular separation devices with an unprecedented resolution and extreme user-friendliness and robustness. The PharmaFluidics’ µPAC™ micro-chip based chromatography cartridges allow to identify substantially more compounds in complex biological samples, including biopsies, proteome digests, culture media or bio-pharmaceutical actives.
More info: www.pharmafluidics.com
About Qbic
More info: www.qbic.be
About PMV
More info: www.pmv.eu
About Theodorus Fund
More info: www.theodorus.be
About Innovation Fund
More info: www.innovationfund.eu
About Volksvermogen
More info: www.volksvermogen.be